Ingalls & Snyder LLC’s Halozyme HALO Stock Holding History

Ingalls & Snyder LLC’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$474K	Buy	7,339 +2,000	+37%	+$141K	0.02%	302
2025 Q4	$359K	Sell	5,339 -73	-1%	-$4.91K	0.01%	342
2025 Q3	$397K	Buy	+5,412	New	+$359K	0.01%	328
2021 Q1	–	Sell	-8,180	Closed	-$349K	–	443
2020 Q4	$349K	Sell	8,180 -4,475	-35%	-$161K	0.02%	326
2020 Q3	$333K	Hold	12,655	–	–	0.02%	281
2020 Q2	$339K	Buy	+12,655	New	+$285K	0.02%	306

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ingalls & Snyder LLC's HALO Position: Q1 2026 in Review

Ingalls & Snyder LLC increased its Halozyme (HALO) stake by 37% in Q1 2026, buying an estimated $141K and bringing the position to 7,339 shares worth $474K. The position accounts for 0.02% of the portfolio, ranked #302.

Ingalls & Snyder LLC first reported a position in HALO in Q2 2020 and has held it in 6 quarters since. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

Ingalls & Snyder LLC held 7,339 shares of Halozyme worth $474K as of Q1 2026.
Ingalls & Snyder LLC bought 2,000 Halozyme shares in Q1 2026, an estimated $141K.
Halozyme made up 0.02% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #302 holding.
Ingalls & Snyder LLC first reported a position in Halozyme in Q2 2020 and has held it in 6 quarters since.
634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.